Reducing Mortality in Adults With Advanced HIV Disease (REVIVE)
Population Health Research Institute
View at source ↗Clinical trial
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Brief summary
A double blinded, placebo-controlled, multicenter trial to evaluate effectiveness of azithromycin prophylaxis on mortality in advanced HIV.
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Trial details
- acronym
- REVIVE
- status
- RECRUITING
- phase
- PHASE3
- study type
- INTERVENTIONAL
- enrollment
- 8000
- sponsor
- Population Health Research Institute
- conditions
- HIV Disease Progression
- interventions
- DRUG: Azithromycin Oral Tablet; DRUG: Placebo oral tablet
- start date
- 2023-05-08
- start date type
- ACTUAL
- primary completion date
- 2028-11-30
- has results
- false
- data source
- ClinicalTrials.gov
- data processed
- 2026-10-29T09:00:05
- modifications
- selected fields only; whitespace normalized; brief summary truncated to 2,000 characters
Record
- Archive ID
- nct:NCT05580666
- Published
- Oct 14, 2022
- Updated
- Sep 3, 2025
- Venue
- ClinicalTrials.gov
- ClinicalTrials.gov
- NCT05580666
- Categories
- HIV Disease Progression
- License
- ClinicalTrials.gov terms (attribution, processing date, modifications noted)
- Provenance
- clinicaltrials